Kathryn Romano Sells 750 Shares of Krystal Biotech, Inc. (NASDAQ:KRYS) Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano sold 750 shares of the firm’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $175.22, for a total value of $131,415.00. Following the sale, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. The trade was a 5.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Krystal Biotech Stock Up 3.4 %

Shares of KRYS opened at $179.25 on Friday. The firm has a market cap of $5.16 billion, a price-to-earnings ratio of 59.95 and a beta of 0.84. The company’s fifty day moving average is $159.41 and its 200-day moving average is $175.26. Krystal Biotech, Inc. has a 12 month low of $141.72 and a 12 month high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, topping the consensus estimate of $1.29 by $0.23. Krystal Biotech had a net margin of 30.69% and a return on equity of 11.41%. The firm had revenue of $91.10 million for the quarter, compared to the consensus estimate of $91.35 million. During the same period in the prior year, the business posted $0.30 earnings per share. The business’s quarterly revenue was up 116.4% on a year-over-year basis. As a group, research analysts predict that Krystal Biotech, Inc. will post 6.14 earnings per share for the current fiscal year.

Analyst Ratings Changes

KRYS has been the subject of several research reports. Citigroup raised their price target on shares of Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a report on Thursday, February 20th. HC Wainwright reissued a “buy” rating and set a $221.00 target price on shares of Krystal Biotech in a research note on Friday. Chardan Capital upped their price target on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price objective on shares of Krystal Biotech in a research report on Thursday, February 20th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $215.83.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB acquired a new position in Krystal Biotech during the third quarter valued at approximately $40,000. GF Fund Management CO. LTD. bought a new stake in shares of Krystal Biotech during the 4th quarter worth $95,000. Huntington National Bank grew its stake in Krystal Biotech by 97.6% in the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after buying an additional 283 shares during the last quarter. Covestor Ltd raised its holdings in Krystal Biotech by 972.7% in the 4th quarter. Covestor Ltd now owns 708 shares of the company’s stock worth $111,000 after acquiring an additional 642 shares during the period. Finally, KBC Group NV lifted its position in Krystal Biotech by 25.9% during the 3rd quarter. KBC Group NV now owns 642 shares of the company’s stock worth $117,000 after acquiring an additional 132 shares during the last quarter. 86.29% of the stock is currently owned by institutional investors and hedge funds.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).